NEW YORK (GenomeWeb News) – Affymetrix today announced a deal with Massachusetts General Hospital to co-develop cancer biomarker tests using Affy's QuantiGene ViewRNA Assay platform.

As part of the deal, Affy has the commercialization rights to new tests resulting from the collaboration. Other terms were not disclosed.

The QuantiGene ViewRNA Assay is an in situ hybridization assay with single-transcript in single-cell detection capability. The platform is for research-use only.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.